CSIG-17. PRMT5 INHIBITION SENSITIZES GLIOBLASTOMA MODELS TO TRAMETINIB TREATMENT

INTRODUCTION: Glioblastoma (GBM) is the most common malignant primary brain tumor. With limited effective therapeutic strategies, prognosis for GBM is very poor. Our previous study shows that the expression of Protein Arginine Methyltransferase 5 (PRMT5) is upregulated in GBM; its inhibition promote...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Neuro Oncol
Главные авторы: Otani, Yoshihiro, Namagiri, Sriya, Thammegowda, Shilpa, Sur, Hannah, Chowdhury, Ashis, Lewis, Cole, Shimizu, Toshihiko, Lee, Tae Jin, Maric, Dragan, Yoo, Ji Young, Heiss, John, Kaur, Balveen, Banasavadi-Siddegowda, Yeshavanth Kumar
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2020
Предметы:
Cell Signaling and Signaling Pathways
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650434/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.129
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы